Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to evaluate whether the use of a rapid pleurodesis protocol using 10% iodopovidone immediately after tunneled pleural catheter placement improves time to IPC removal compared to patients who receive an IPC alone.


Clinical Trial Description

Patients will be screened throughout the year as part of the clinical referral process to the Interventional Pulmonology service at the Hospital of the University of Pennsylvania for the management of a malignant pleural effusion. Patients eligible for inclusion based on the clinical evaluation will be approached for enrollment. Written consent will be obtained. Patients will subsequently undergo placement of a IPC under MAC as per standard clinical practice followed by complete drainage of the pleural space. Patients randomized to the rapid pleurodesis protocol arm will received 20mL of 10% iodopovidone mixed with 80mL of normal saline instilled intrapleurally through the IPC. Patients randomized to the standard of care arm will have 100mL of normal saline (placebo) instilled intrapleurally through the IPC. The mixture will be allowed to dwell for 2 hours and then completely evacuated through the IPC and the patient will be discharged home.

After discharge, all patients will continue to drain their IPC on a daily basis for 7 days. Following this, all patients will continue to drain their IPC on an every-other-day basis until total IPC output is less than 50ml per session over 3 consecutive sessions. At which point they will be asked to undergo a clamp trial of no drainage for 7 days followed by a reattempt at drainage. Patients without return of symptoms over those 7 days and minimal drainage afterwards (<50ml) will be seen in the office for possible IPC removal. Patients with return of symptoms during those 7 days or more than minimal drainage afterwards (>50mL) will be asked to continue drainage until total IPC output is again less than 50mL per session over 3 sessions.

After a passed clamp trial, patients will be evaluated in the office with a bedside ultrasound to assess for pleural apposition in 5 of 6 designated points and the absence of pleural effusions. If all criteria are met, the IPC is removed. If there is evidence of residual effusion, continued drainage will be advised.

All patients will be evaluated in the office on day 7, day 14, day 30, day 60 and day 90 after IPC placement. On each visit they will be assessed for pleural apposition with ultrasound. At day 30, 60, and 90 all patients will receive a global health related questionnaire (EORTC QLQ30) and a symptom questionnaire. At 90 days, complications rate will be assessed for the entire study period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03325192
Study type Interventional
Source University of Pennsylvania
Contact
Status Terminated
Phase N/A
Start date December 12, 2017
Completion date July 9, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05693727 - Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
Recruiting NCT05910112 - Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
Completed NCT03272997 - The Value of PET-CT in Pleural Effusions
Completed NCT03270215 - The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
Completed NCT00099541 - Non-small Cell Lung Cancer Registry Phase 4
Recruiting NCT04844827 - Pleural Carcinomatosis Tissue Banking
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Recruiting NCT05278975 - Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Phase 1/Phase 2
Recruiting NCT02407912 - Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer N/A
Terminated NCT00316134 - Multiple Biomarkers in Undiagnosed Pleural Effusion N/A
Not yet recruiting NCT06275178 - Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
Recruiting NCT04684459 - Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis Early Phase 1
Recruiting NCT04670562 - Longitudinal Follow up of Patients With Pleural Effusion
Not yet recruiting NCT02805062 - Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy N/A
Completed NCT03276715 - Prognostic Factors on Malignant Pleural Effusion
Completed NCT03394105 - Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Terminated NCT02702700 - Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies Phase 1
Recruiting NCT02045121 - Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management N/A
Completed NCT01670786 - Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion Phase 4